Home
Sitemap
中文版
English
Drugs
Medical Devices
Consultation Services
Health Technology Assessment
International Cooperation
About Us
FAQ
Drugs
Home
FAQ
Drugs
All
Class
Technical Dossier Review of Drugs
New Drug Application (NDA)
Investigational New Drug Application(IND)
Application of Bridging Study Evaluation (BSE)
Active Pharmaceutical Ingredient (API)
Abbreviated New Drug Application (ANDA)
Drug Substance
CIRB
Botanical drug
Instruction Drugs
Postapproval Changes
Investigational New Drug Application(IND)
No.
Class
Title
31
Drug Substance
Is it suitable to use the USP<231>heavy metals methods to control all of the elemental impurities?
32
Drug Substance
If a drug substance may contain different numbers of solvated water (ex: anhydrous, hemihydrate, monohydrate or dihydrate forms), is it required to denote the numbers of solvated water in the name of the drug substance?
33
Drug Substance
How does one justify the suitability of a primary reference standard if the primary reference standard is not purchased from a pharmacopoeial or equivalent sources?
34
Drug Substance
When submitting a DMF or API registration application, if the specification of the drug substance is established based requirements listed in a compendial monograph, what should other requirements be noted?
35
Drug Substance
If an active pharmaceutical ingredient (API) has an amorphous crystal form, is it necessary to provide analysis results for its crystal form?
36
Drug Substance
If a drug substance is not included in monographing pharmacopeia, what are the requirements for the drug substance specification?
37
Drug Substance
According to the DMF technical information check list promulgated by TFDA, the drug substance process validation data may be replaced by the process validation protocol and a representative batch record. Is it required for the representative batch record to be from one of the process validation batches?
38
Drug Substance
What are the requirements for filing a DMF or API application where the drug substance is a mixture of two other drug substances?
39
Drug Substance
Is it required to submit separate DMFs for the same drug substance but with different grades of particle sizes (different particle size distributions) ?
40
Drug Substance
If the submitting drug substance with two or more crystalline hydrate formulas, should DMF divide into different applications? If a drug substance has different solvated forms (hydrates), is it required to file a separate DMF for each of the hydrate?
Page
Page:
4/24
‧ Total:
233
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
Drugs
Medical Devices
Consultation Services
Health Technology Assessment
International Cooperation